1. Prediction of single-cell RNA expression profiles in live cells by Raman microscopy with Raman2RNA.
- Author
-
Kobayashi-Kirschvink KJ, Comiter CS, Gaddam S, Joren T, Grody EI, Ounadjela JR, Zhang K, Ge B, Kang JW, Xavier RJ, So PTC, Biancalani T, Shu J, and Regev A
- Subjects
- Mice, Animals, Cell Differentiation genetics, Transcriptome genetics, Gene Expression Profiling methods, Fibroblasts metabolism, Fibroblasts cytology, Induced Pluripotent Stem Cells metabolism, Induced Pluripotent Stem Cells cytology, Sequence Analysis, RNA methods, Microscopy methods, In Situ Hybridization, Fluorescence methods, RNA genetics, RNA metabolism, Single-Cell Analysis methods, Spectrum Analysis, Raman methods
- Abstract
Single-cell RNA sequencing and other profiling assays have helped interrogate cells at unprecedented resolution and scale, but are inherently destructive. Raman microscopy reports on the vibrational energy levels of proteins and metabolites in a label-free and nondestructive manner at subcellular spatial resolution, but it lacks genetic and molecular interpretability. Here we present Raman2RNA (R2R), a method to infer single-cell expression profiles in live cells through label-free hyperspectral Raman microscopy images and domain translation. We predict single-cell RNA sequencing profiles nondestructively from Raman images using either anchor-based integration with single molecule fluorescence in situ hybridization, or anchor-free generation with adversarial autoencoders. R2R outperformed inference from brightfield images (cosine similarities: R2R >0.85 and brightfield <0.15). In reprogramming of mouse fibroblasts into induced pluripotent stem cells, R2R inferred the expression profiles of various cell states. With live-cell tracking of mouse embryonic stem cell differentiation, R2R traced the early emergence of lineage divergence and differentiation trajectories, overcoming discontinuities in expression space. R2R lays a foundation for future exploration of live genomic dynamics., Competing Interests: Competing interests A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was a scientific advisory board member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. A.R. is an employee of Genentech from 1 August 2020 with equity in Roche. T.B., S.G. and T.J. are employees of Genentech from 1 Feburary 2021, 29 March 2021 and 5 June 2023, respectively. J.S. is a scientific advisor for Arcadia Science. A patent application has been filed by the Broad Institute related to this work. The other authors declare no competing interests., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2024
- Full Text
- View/download PDF